Objective To investigate the effects of early continuous renal replacement therapy(CRRT) on the improvement of clinical symptoms,inflammatory factors and prognosis of severe acute pancreatitis(SAP).Methods A total of 110 SAP patients admitted to Shangqiu No.3 People's Hospital from January 2022 to January 2023 were selected as the study subjects.They were assigned into control group(n=55) and observation group(n=55) according to different treatment regimens.Patients in the control group were treated with conventional Western medicine,and those in the observation group were treated with conventional Western medicine combined with CRRT.The clinical efficacy,time of clinical symptom improvement,health status(acute physiology and chronic health evaluation Ⅱ [APACHE Ⅱ],modified Marshall organ failure score,ranson's criteria for pancreatitis mortality),inflammatory factors(procalcitonin [PCT],interleukin-17 [IL-17],high mobility group protein B1 [HMGB1]),urinary amylase,and immune function(CD3+,CD4+,immunoglobulin A [IgA],immunoglobulin G [IgG],immunoglobulin M [IgM]) before and after treatment were compared.The incidence of complications was compared between the two groups as well.Results The total effective rate of the observation group was significantly higher than that of control group(92.73% VS 72.73%,P<0.05).The time of clinical symptom improvement was significantly shorter in the observation group than that of the control group(P<0.05).After treatment,patients in the observation group had significantly lower APACHE Ⅱ([3.87±1.19]points VS [7.42±2.17]points),modified Marshall organ failure score([1.08±0.33]points VS [1.76±0.49]points) and Ranson's Criteria for pancreatitis mortality([1.37±0.35]points VS [2.29±0.63]points) than those of control group(P<0.05).PCT([1.57±0.42]μg/L VS [3.08±0.92]μg/L),IL-17([10.32±2.86]ng/L VS [20.71±5.91]ng/L),HMGB1([3.16±0.85]ng/mL VS [7.09±1.13]ng/mL) and urinary amylase([103.65±30.55]U/L VS [148.74±39.58]U/L) after treatment were significantly lower in the observation group than those of control group(P<0.05).CD3+([69.65%±8.32]% VS [62.07%±9.03]%),CD4+([37.49%±6.49]% VS [32.07%±5.69]%) and IgA([12.86±3.28]g/L VS [7.26±2.13]g/L) were significantly higher,while IgG([1.22±0.30]g/L VS [5.94±1.28]g/L) and IgM([1.17±0.28]g/L VS [1.88±0.42]g/L) were significantly lower in the observation group than those of control group(P<0.05).There was no significant difference in the rate of complications between the two groups(P>0.05).Conclusion Early CRRT is effective and safe in the treatment of SAP,which can improve clinical symptoms,promote disease rehabilitation,correct the disorder of inflammatory factor-urine amylase level,and improve immune function.
ZHAO Yi-han
,
LI Yan-hua
,
CHEN Jing-jing
. Clinical study of early continuous renal replacement therapy for improving severe acute pancreatitis[J]. CHINESE JOURNAL OF CONVALESCENT MEDICINE, 2024
, 33(8)
: 103
-107
.
DOI: 10.13517/j.cnki.ccm.2024.08.023
[1] 郭迎雪,崔大鹏,聂双发,等.柴芩承气汤早期内服与灌肠联合高强度综合疗法治疗重症急性胰腺炎临床研究[J].陕西中医,2022,43(8):1041-1044.
[2] 徐刘涛,李良.穴位针刺联合肠内营养支持在重症急性胰腺炎患者中的应用观察[J].中国疗养医学,2022,31(8):871-873.
[3] 王海宾. 连续性肾脏替代治疗对脓毒症患者炎症因子及疗效的影响[J].山西医药杂志,2020,49(2):178-180.
[4] 吴林,孔晓霞,郑桂贞,等.早期CRRT联合前列地尔治疗高脂血症性急性重症胰腺炎[J].西部医学,2022,34(2):270-275.
[5] 中华医学会外科学分会胰腺外科学组.急性胰腺炎诊治指南(2014版)[J].中华消化外科杂志,2015,14(1):1-5.
[6] 信然然,霍丽丽,刘岩.前列地尔联合血必净治疗急性重症胰腺炎的疗效及对血清肿瘤坏死因子-α白细胞介素-6降钙素原的影响[J].山西医药杂志,2020,49(2):137-140.
[7] HOSSEINI M,RAMAZANI J.Comparison of acute physiology and chronic health evaluation II and Glasgow Coma Score in predicting the outcomes of Post Anesthesia Care Unit's patients[J].Saudi J Anaesth,2015,9(2):136-141.
[8] BRAASCH M C,HALIMEH B N,GUIDRY C A.Availability of Multiple Organ Failure Score Components in Surgical Patients[J].Surg Infect (Larchmt),2022,23(2):178-182.
[9] ONG Y,SHELAT V G.Ranson score to stratify severity in Acute Pancreatitis remains valid-Old is gold[J].Expert Rev Gastroenterol Hepatol,2021,15(8):865-877.
[10] 吕春月. 白蛋白-胆红素评分对重症胰腺炎患者的预后评估分析[J].中国疗养医学,2022,31(1):95-98.
[11] 卢武,周煦,吴艳红,等.乌司他丁联合连续性肾脏替代治疗对严重脓毒症患者炎症反应和血流动力学的影响[J].现代生物医学进展,2020,20(17):3256-3259.
[12] 魏义,任红旗,王斌,等.连续肾脏替代疗法对重症急性胰腺炎患者肠黏膜功能、炎性介质以及氧化应激指标的影响[J].药物生物技术,2020,27(6):523-526.
[13] 王月兴,邓丽娟,曾凡清,等.持续肾替代治疗对重症急性胰腺炎患者PCT、IL-17、IL-6、HMGB1水平的影响及其临床意义[J].中国现代医学杂志,2022,32(12):20-24.
[14] 雷忠,张开龙,殷燕.连续性肾替代治疗脓毒症并发急性肾损伤患者疗效及其对血清炎症因子影响[J].中国中西医结合肾病杂志,2021,22(9):823-824.
[15] 苏莹. 小剂量糖皮质激素联合奥曲肽对重症急性胰腺炎的疗效及对免疫功能、血小板活化因子及肽素的影响[J].中国急救复苏与灾害医学杂志,2021,16(2):173-177.